Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia

Research output: Contribution to journalArticle


The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved.


  • Mohd Arifin Kaderi
  • Mahmoud Mansouri
  • Norafiza Zainuddin
  • Nicola Cahill
  • Rebeqa Gunnarsson
  • Mattias Jansson
  • Eva Kimby
  • Anna Aleskog
  • Jeanette Lundin
  • Bengt Glimelius
  • Mads Melbye
  • Gunnar Juliusson
  • Jesper Jurlander
  • Richard Rosenquist
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology


  • Genomic aberrations, Prognostic markers, status, IGHV mutational, Binet stage, MDM2 SNP309, Chronic lymphocytic leukemia
Original languageEnglish
Pages (from-to)335-339
JournalLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
Issue number3
Publication statusPublished - 2010
Publication categoryResearch

Bibliographic note

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hematology/Transplantation (013022014)